Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

Teva Pharmaceutical (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) have launched their biosimilar targeting Johnson & Johnson’s (NYSE ...

Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to J&J's blockbuster immunosuppressive ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional ...